On June 26th, the Department of Health and Social Services' (HSS) newly restructured Advisory Committee on Immunization Practices (ACIP) made several decisive votes. The most prominent among them was the recommendation for Merck's respiratory syncytial virus (RSV) monoclonal antibody drug, clesrovimab, and turning down a constituent in certain flu vaccines. The drug Clesrovimab is recommended…